The gov. begins research on preferential tx

By Lee, Jeong-Hwan | translator Choi HeeYoung

21.10.20 06:18:46

가나다라 0

From drug price support to post-adjustment incentives and R&D investment linkage are also considered

The MOHW will place an order for research on the 19th through KHIDI. The results will be announced in May next year

The MOHW has launched a research service to prepare preferential measures for new drugs developed by innovative pharmaceutical companies in Korea. The policy is to innovate pharmaceutical companies and achieve health insurance fiscal consistency, such as giving incentives when adjusting drug prices and supporting drug prices linked to R&D investment scale.

On the 19th, the MOHW completed an order to Korea Online EProcurement System for "Research on Pharmaceutical Price Support Policy of Innovative Pharmaceutical Companies in Conformity with International Trade Order" through the KHIDI.

Regarding the background of research on drug preferential treatment for innovative pharmaceutical compa

Lee, Jeong-Hwan(junghwanss@dailypharm.com)

If you want to see the full article, please JOIN US (click)